Ingavirín môže byť sľubnou zlúčeninou v boji proti koronavírusu
2 vyvolávajúcemu ťažký akútny respiračný syndróm (SARS-CoV-2)

J 2020

Ingavirín môže byť sľubnou zlúčeninou v boji proti koronavírusu 2 vyvolávajúcemu ťažký akútny respiračný syndróm (SARS-CoV-2)

MALÍK, Ivan, Gustav KOVÁČ, Tereza PADRTOVÁ a Lucia HUDECOVÁ

Základní údaje

Originální název

Ingavirín môže byť sľubnou zlúčeninou v boji proti koronavírusu 2 vyvolávajúcemu ťažký akútny respiračný syndróm (SARS-CoV-2)

Název česky

Ingavirin může být slibnou sloučeninou v boji proti koronaviru 2 vyvolávajícímu těžký akutní respirační syndrom (SARS-CoV-2)

Autoři

MALÍK, Ivan (703 Slovensko, garant, domácí), Gustav KOVÁČ (703 Slovensko), Tereza PADRTOVÁ (203 Česká republika, domácí) a Lucia HUDECOVÁ (703 Slovensko)

Vydání

Česká a slovesnká farmacie, 2020, 1210-7816

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30107 Medicinal chemistry

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

https://www.prolekare.cz/casopisy/ceska-slovenska-farmacie/2020-3-10/ingavirin-moze-byt-slubnou-zluceninou-v-boji-proti-koronavirusu-2-vyvolavajucemu-tazky-akutny-respiracny-syndrom-sars-cov-2-123699

Kód RIV

RIV/00216224:14160/20:00117529

Organizační jednotka

Farmaceutická fakulta

Klíčová slova anglicky

SARS-CoV-2 • COVID-19 • ingavirin • heterogeneous nuclear ribonucleoproteins • nucleocapsid (N) protein

Štítky

rivok, ÚChL

Příznaky

Recenzováno

Změněno: 3. 3. 2021 10:52, Mgr. Hana Hurtová

Anotace

V originále

The Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease-19 (COVID-19) pandemic, caused by the virus, have changed the world in just half a year. Lack of effective treatment, coupled with etiology of COVID-19, has resulted in more than 500,000 confirmed deaths at the time of writing, and the global economy is at an unseen unprecedented low level with unknown near- and long-term consequences. Ingavirin has been considered a non-toxic broad-spectrum antiviral with a complex mechanism of action. The molecule was originally designed for the prophylaxis and treatment of flu caused by both Influenza A and B viruses and for the treatment of viral causes of acute respiratory illness. The article hypothesized that the efficiency of given 1H-imidazol-4-yl heterocyclic scaffold-containing compound against SARS-CoV-2 might be connected with its ability to interfere with specific heterogeneous nuclear ribonucleoproteins (A1, for example). These specific cellular RNA-binding proteins showed affinity to Severe Acute Respiratory Coronavirus (SARS-CoV) nucleocapsid (N) protein, which shared high homology with the N protein of SARS-CoV-2 and the fact was expressed by a sequence identity of 90.52%. Impairing of the interactions between nuclear ribonucleoproteins and nucleocapsid (N) protein of SARS-CoV-2 might result in the inhibition of a viral replication cycle. Additional immunomodulating properties of ingavirin could be favorable for induction of adaptive immunity of host cells.

Citovat

MALÍK, Ivan, Gustav KOVÁČ, Tereza PADRTOVÁ a Lucia HUDECOVÁ. Ingavirín môže byť sľubnou zlúčeninou v boji proti koronavírusu 2 vyvolávajúcemu ťažký akútny respiračný syndróm (SARS-CoV-2). Česká a slovesnká farmacie. 2020, roč. 69, č. 3, s. 107-111. ISSN 1210-7816.

@article{1717482,
   author = {Malík, Ivan and Kováč, Gustav and Padrtová, Tereza and Hudecová, Lucia and Kováč, Gustav and Padrtová, Tereza and Hudecová, Lucia},
   article_number = {3},
   keywords = {SARS-CoV-2 • COVID-19 • ingavirin • heterogeneous nuclear ribonucleoproteins • nucleocapsid (N) protein},
   language = {eng},
   issn = {1210-7816},
   journal = {Česká a slovesnká farmacie},
   title = {Ingavirín môže byť sľubnou zlúčeninou v boji proti koronavírusu 2 vyvolávajúcemu ťažký akútny respiračný syndróm (SARS-CoV-2)},
   url = {https://www.prolekare.cz/casopisy/ceska-slovenska-farmacie/2020-3-10/ingavirin-moze-byt-slubnou-zluceninou-v-boji-proti-koronavirusu-2-vyvolavajucemu-tazky-akutny-respiracny-syndrom-sars-cov-2-123699},
   volume = {69},
   year = {2020}
}

TY  - JOUR
ID  - 1717482
AU  - Malík, Ivan - Kováč, Gustav - Padrtová, Tereza - Hudecová, Lucia - Kováč, Gustav - Padrtová, Tereza - Hudecová, Lucia
PY  - 2020
TI  - Ingavirín môže byť sľubnou zlúčeninou v boji proti koronavírusu 2 vyvolávajúcemu ťažký akútny respiračný syndróm (SARS-CoV-2)
JF  - Česká a slovesnká farmacie
VL  - 69
IS  - 3
SP  - 107-111
EP  - 107-111
SN  - 12107816
KW  - SARS-CoV-2 • COVID-19 • ingavirin • heterogeneous nuclear ribonucleoproteins • nucleocapsid (N) protein
UR  - https://www.prolekare.cz/casopisy/ceska-slovenska-farmacie/2020-3-10/ingavirin-moze-byt-slubnou-zluceninou-v-boji-proti-koronavirusu-2-vyvolavajucemu-tazky-akutny-respiracny-syndrom-sars-cov-2-123699
L2  - https://www.prolekare.cz/casopisy/ceska-slovenska-farmacie/2020-3-10/ingavirin-moze-byt-slubnou-zluceninou-v-boji-proti-koronavirusu-2-vyvolavajucemu-tazky-akutny-respiracny-syndrom-sars-cov-2-123699
N2  - The Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease-19 (COVID-19) pandemic, caused by the virus, have changed the world in just half a year. Lack of effective treatment, coupled with etiology of COVID-19, has resulted in more than 500,000 confirmed deaths at the time of writing, and the global economy is at an unseen unprecedented low level with unknown near- and long-term consequences. Ingavirin has been considered a non-toxic broad-spectrum antiviral with a complex mechanism of action. The molecule was originally designed for the prophylaxis and treatment of flu caused by both Influenza A and B viruses and for the treatment of viral causes of acute respiratory illness. The article hypothesized that the efficiency of given 1H-imidazol-4-yl heterocyclic scaffold-containing compound against SARS-CoV-2 might be connected with its ability to interfere with specific heterogeneous nuclear ribonucleoproteins (A1, for example). These specific cellular RNA-binding proteins showed affinity to Severe Acute Respiratory Coronavirus (SARS-CoV) nucleocapsid (N) protein, which shared high homology with the N protein of SARS-CoV-2 and the fact was expressed by a sequence identity of 90.52%. Impairing of the interactions between nuclear ribonucleoproteins and nucleocapsid (N) protein of SARS-CoV-2 might result in the inhibition of a viral replication cycle. Additional immunomodulating properties of ingavirin could be favorable for induction of adaptive immunity of host cells.
ER  -

MALÍK, Ivan, Gustav KOVÁČ, Tereza PADRTOVÁ a Lucia HUDECOVÁ. Ingavirín môže byť sľubnou zlúčeninou v boji proti koronavírusu 2 vyvolávajúcemu ťažký akútny respiračný syndróm (SARS-CoV-2). \textit{Česká a slovesnká farmacie}. 2020, roč.~69, č.~3, s.~107-111. ISSN~1210-7816.

Podrobný výpis o publikaci